ATE334677T1 - Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation - Google Patents
Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregationInfo
- Publication number
- ATE334677T1 ATE334677T1 AT03749892T AT03749892T ATE334677T1 AT E334677 T1 ATE334677 T1 AT E334677T1 AT 03749892 T AT03749892 T AT 03749892T AT 03749892 T AT03749892 T AT 03749892T AT E334677 T1 ATE334677 T1 AT E334677T1
- Authority
- AT
- Austria
- Prior art keywords
- metabolite
- valsartan
- platelet aggregation
- ischemic
- acute
- Prior art date
Links
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 239000002207 metabolite Substances 0.000 abstract 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- ICSQZMPILLPFKC-XLDIYJRPSA-N 4-Hydroxyvalsartan Chemical compound C1=CC(CN(C(=O)CCC(O)C)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICSQZMPILLPFKC-XLDIYJRPSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010038563 Reocclusion Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38037302P | 2002-05-14 | 2002-05-14 | |
| US39501402P | 2002-07-11 | 2002-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334677T1 true ATE334677T1 (de) | 2006-08-15 |
Family
ID=29423705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03749892T ATE334677T1 (de) | 2002-05-14 | 2003-05-13 | Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20050197372A1 (de) |
| EP (1) | EP1505965B1 (de) |
| JP (1) | JP4467427B2 (de) |
| KR (1) | KR101005367B1 (de) |
| CN (1) | CN100408035C (de) |
| AT (1) | ATE334677T1 (de) |
| AU (1) | AU2003267447B8 (de) |
| BR (1) | BR0310018A (de) |
| CA (1) | CA2482541A1 (de) |
| CY (1) | CY1105638T1 (de) |
| DE (1) | DE60307265T2 (de) |
| DK (1) | DK1505965T3 (de) |
| ES (1) | ES2268403T3 (de) |
| HK (1) | HK1074395A1 (de) |
| IL (2) | IL164774A0 (de) |
| MX (1) | MXPA04011282A (de) |
| NO (1) | NO20045245L (de) |
| NZ (1) | NZ536295A (de) |
| PL (1) | PL371728A1 (de) |
| PT (1) | PT1505965E (de) |
| RU (1) | RU2334512C2 (de) |
| TW (1) | TWI299663B (de) |
| WO (1) | WO2003094915A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| TW200920371A (en) * | 2007-08-29 | 2009-05-16 | Orion Corp | A combination treatment |
| US10478404B2 (en) | 2014-01-24 | 2019-11-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| CN110078640B (zh) * | 2019-03-29 | 2022-04-05 | 浙江美诺华药物化学有限公司 | 一种缬沙坦中间体的合成方法 |
| CN111643557B (zh) * | 2020-05-26 | 2022-02-22 | 四川省骨科医院 | 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1612280B1 (de) * | 1993-04-05 | 2011-08-31 | University of Utah Research Foundation | Diagnose und Behandlung von Williams Syndrom |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| EP1867342A1 (de) * | 1999-07-21 | 2007-12-19 | Takeda Pharmaceutical Company Limited | Wirkstoffe zum Lindern von Beschwerden infolge von zerebrovaskulären Erkrankungen und zum Hemmen deren Fortschreitens |
| AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| AU2001285768B2 (en) * | 2000-06-22 | 2005-03-10 | Novartis Ag | Solid valsartan pharmaceutical compositions |
-
2003
- 2003-05-12 TW TW092112854A patent/TWI299663B/zh not_active IP Right Cessation
- 2003-05-13 RU RU2004136583/15A patent/RU2334512C2/ru not_active IP Right Cessation
- 2003-05-13 DE DE60307265T patent/DE60307265T2/de not_active Expired - Lifetime
- 2003-05-13 BR BR0310018-9A patent/BR0310018A/pt not_active IP Right Cessation
- 2003-05-13 PL PL03371728A patent/PL371728A1/xx unknown
- 2003-05-13 IL IL16477403A patent/IL164774A0/xx unknown
- 2003-05-13 DK DK03749892T patent/DK1505965T3/da active
- 2003-05-13 AU AU2003267447A patent/AU2003267447B8/en not_active Ceased
- 2003-05-13 ES ES03749892T patent/ES2268403T3/es not_active Expired - Lifetime
- 2003-05-13 EP EP03749892A patent/EP1505965B1/de not_active Expired - Lifetime
- 2003-05-13 US US10/514,299 patent/US20050197372A1/en not_active Abandoned
- 2003-05-13 AT AT03749892T patent/ATE334677T1/de active
- 2003-05-13 CN CNB03810864XA patent/CN100408035C/zh not_active Expired - Fee Related
- 2003-05-13 PT PT03749892T patent/PT1505965E/pt unknown
- 2003-05-13 NZ NZ536295A patent/NZ536295A/en not_active IP Right Cessation
- 2003-05-13 KR KR1020047018282A patent/KR101005367B1/ko not_active IP Right Cessation
- 2003-05-13 CA CA002482541A patent/CA2482541A1/en not_active Abandoned
- 2003-05-13 MX MXPA04011282A patent/MXPA04011282A/es active IP Right Grant
- 2003-05-13 JP JP2004503001A patent/JP4467427B2/ja not_active Expired - Lifetime
- 2003-05-13 WO PCT/EP2003/004997 patent/WO2003094915A1/en active IP Right Grant
-
2004
- 2004-10-21 IL IL164774A patent/IL164774A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045245A patent/NO20045245L/no not_active Application Discontinuation
-
2005
- 2005-07-21 HK HK05106187A patent/HK1074395A1/xx not_active IP Right Cessation
-
2006
- 2006-09-28 CY CY20061101409T patent/CY1105638T1/el unknown
-
2009
- 2009-02-02 US US12/363,926 patent/US20100048654A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100048654A1 (en) | 2010-02-25 |
| DE60307265T2 (de) | 2007-07-19 |
| US20050197372A1 (en) | 2005-09-08 |
| AU2003267447B8 (en) | 2009-08-06 |
| RU2004136583A (ru) | 2005-09-10 |
| PT1505965E (pt) | 2006-11-30 |
| EP1505965B1 (de) | 2006-08-02 |
| IL164774A (en) | 2010-04-29 |
| ES2268403T3 (es) | 2007-03-16 |
| CY1105638T1 (el) | 2010-12-22 |
| CN1652774A (zh) | 2005-08-10 |
| NO20045245L (no) | 2004-11-30 |
| BR0310018A (pt) | 2005-02-15 |
| DK1505965T3 (da) | 2006-11-13 |
| TWI299663B (en) | 2008-08-11 |
| CA2482541A1 (en) | 2003-11-20 |
| JP4467427B2 (ja) | 2010-05-26 |
| DE60307265D1 (de) | 2006-09-14 |
| EP1505965A1 (de) | 2005-02-16 |
| NZ536295A (en) | 2006-12-22 |
| MXPA04011282A (es) | 2005-01-25 |
| AU2003267447A1 (en) | 2003-11-11 |
| PL371728A1 (en) | 2005-06-27 |
| CN100408035C (zh) | 2008-08-06 |
| IL164774A0 (en) | 2005-12-18 |
| KR20050000532A (ko) | 2005-01-05 |
| HK1074395A1 (en) | 2005-11-11 |
| KR101005367B1 (ko) | 2010-12-30 |
| WO2003094915A1 (en) | 2003-11-20 |
| TW200410686A (en) | 2004-07-01 |
| JP2005529913A (ja) | 2005-10-06 |
| AU2003267447B2 (en) | 2006-11-02 |
| RU2334512C2 (ru) | 2008-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1074395A1 (en) | Use of the metabolite of valsartan to inhibit platelet aggregation | |
| Sankaranarayanan et al. | How does chronic atrial fibrillation influence mortality in the modern treatment era? | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| DK1532269T3 (da) | 1L1RL-1 som markør for kardiovaskulær sygdom | |
| AR033510A1 (es) | Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestiva | |
| NZ597024A (en) | Cardiovascular related uses of il-1beta antibodies and binding fragments thereof | |
| NO20032765L (no) | Terapeutisk forening av amlodipin og benazepril/benazeprilat | |
| NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
| NO20083003L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer | |
| RU2008150477A (ru) | Фармацевтическая композиция, содержащая амлодипин и лозартан | |
| EP1125580A3 (de) | Verfahren zur Behandlung von diabetischer Herzmyopathie mit Glykogen Phosphorylaseinhibitoren | |
| WO2006110887A3 (en) | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling | |
| DK1728507T3 (da) | Anvendelse af vitamin K for at omvende forkalkning af blodkar | |
| MX2007005367A (es) | Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. | |
| HK1085467A1 (en) | Substituted heterocyclic compounds | |
| JP2007514769A5 (de) | ||
| JP2013514981A5 (de) | ||
| NO20071107L (no) | 1,1,2,2-tetra(hetero)aryletaner eller 1,1,2-tri(hetero)aryl-2-heterosyklyletaner som kaliumkanalinhibitorer | |
| WO2006037958A3 (en) | Treatment of helminth infection by inhibition of tyrosinase | |
| DE602004027515D1 (de) | Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz | |
| NZ622549A (en) | Novel crystalline form of zofenopril calcium | |
| Giles | The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol | |
| AR042000A1 (es) | Uso de fosinopril para reducir los eventos cardiovasculares en pacientes dializados | |
| RU2008128956A (ru) | Способ оценки эффективности тромболитической терапии у больных с острым коронарным синдромом | |
| Pericleous | Type II heparin-induced thrombocytopenia in an elderly patient: case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1505965 Country of ref document: EP |